Feb 9, 2024
Takeda Pharmaceutical’s drug candidate, TAK-861, has proven to be effective and safe in treating type 1 narcolepsy in a mid-stage study, moving it to the final stage of clinical trials. The drug showed significant improvement in patients without any serious adverse events reported. Takeda is relying on TAK-861 to help offset the potential sales decline expected when its ulcerative colitis drug, Entyvio, loses patent protection.
Feb 9, 2024
China has implemented new rules and guidelines for the patent law, including the introduction of a pharmaceutical patent term compensation system. This system allows for the extension of patent terms for new drugs that have been approved for marketing in China. The compensation period can be up to five years, with a total effective patent term not exceeding 14 years after marketing approval. The scope of compensation includes patents for new drug products, methods of preparing drugs, and medical use, but does not cover veterinary drugs, pesticides, or medical devices.
Feb 8, 2024
Pharmaceutical CEOs testified before the U.S. Senate Committee on Health, Education Labor & Pensions, discussing high drug prices and patents. Senator Bernie Sanders challenged pharmaceutical companies on their spending priorities and questioned drug pricing disparities between the U.S. and other countries. The role of patents in maintaining high drug prices was also a focus of the hearing. The Leonard D. Schaeffer Center for Health Policy & Economics suggested that implementing European-style pricing policies could decrease Americans' life expectancy. The U.S. Chamber of Commerce criticized the hearing as political grandstanding.